Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| No NIH funding | Other Identifier | 10.11.23 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The overarching goal of this study is to characterize the effects of cannabinoids on working and episodic memory.
This study will be achieved by studying the acute effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis and a cannabinoid-1 receptor (CB1R) agonist, on a wide range of memory tasks in healthy human subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| THC | Active Comparator | Active THC (0.0015mg/kg-0.03mg/kg) administered over 20 minutes. |
|
| Placebo | Placebo Comparator | Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| THC | Drug | Active THC (0.0015-0.03 mg/kg) administered over 20 minutes. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Rey Auditory Verbal Learning Test (RAVLT) | a measure of verbal episodic memory | +35 minutes after infusion |
| N-Back Task | a measure of working memory | +65 minutes after infusion |
| Measure | Description | Time Frame |
|---|---|---|
| Clinician Administered Dissociative Symptoms Scale (Total Score) | Baseline, +10, +85, and +240 minutes after the first infusion | |
| Visual Analog Scale (Total Score) | a measure of THC intoxication |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mohini Ranganathan, M.D. | Assistant Professor | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| VA Connecticut Healthcare System | West Haven | Connecticut | 06516 | United States |
Not provided
| ID | Term |
|---|---|
| D002189 | Marijuana Abuse |
| D011618 | Psychotic Disorders |
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D013759 | Dronabinol |
| ID | Term |
|---|---|
| D002186 | Cannabinoids |
| D013729 | Terpenes |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes. |
|
| Baseline, +10, +85, +240 minutes after the first infusion |